{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:05Z","timestamp":1792465625500,"version":"4.5.0"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore herpes zoster (<jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content>) rates and live zoster vaccine (<jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content>) safety in a subset of patients with rheumatoid arthritis who received <jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content> before tofacitinib \u00b1 methotrexate (<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>), or adalimumab (<jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>) plus <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> in the ORAL Strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">ORAL<\/jats:styled-content> Strategy was a 1\u2010year, phase IIIb\/IV, randomized, triple\u2010dummy, active\u2010comparator\u2013controlled study. <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>\u2010inadequate responder patients received tofacitinib 5\u00a0mg twice daily (BID), tofacitinib 5\u00a0mg BID plus <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>, or <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> 40 mg every other week plus <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> (1:1:1 randomization). Eligible patients age \u226550 years could opt to receive <jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content> 28 days before initiating study treatment. <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> incidence rates (<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s;\u00a0patients with events per 100 patient\u2010years) were calculated. Opportunistic <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> infections (multidermatomal\/disseminated), serious <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> events, and <jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content>\u2010related adverse events were monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In <jats:styled-content style=\"fixed-case\">ORAL<\/jats:styled-content> Strategy, 216 of 1,146 patients (18.8%) received <jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content>. Overall, 18 patients (1.6%) developed <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> (vaccinated: n = 3; nonvaccinated: n = 15). <jats:styled-content style=\"fixed-case\">HZ IR<\/jats:styled-content>s were 1.1 (95% confidence interval [95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>] 0.3\u20132.9), 2.3 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.0\u20134.6), and 1.7 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.6\u20133.7) for tofacitinib monotherapy, tofacitinib plus <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>, respectively, and were generally similar between vaccinated and nonvaccinated patients. Three multidermatomal, 1 disseminated, and 2 serious <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> events occurred. No vaccinated patients had zoster\u2010like lesions within 42 days of vaccination; 1 patient had vaccination\u2010site erythema.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content> was well tolerated, and <jats:styled-content style=\"fixed-case\">HZ IR<\/jats:styled-content>s were generally similar between treatment groups and vaccinated versus nonvaccinated patients. However, <jats:styled-content style=\"fixed-case\">ORAL<\/jats:styled-content> Strategy was not powered for comparisons between vaccinated and nonvaccinated patients because &lt;20% of all patients were vaccinated. Furthermore, <jats:styled-content style=\"fixed-case\">LZV<\/jats:styled-content> has been shown to be effective only in ~50% of individuals.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.24010","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T14:50:15Z","timestamp":1560783015000},"page":"353-359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb\/IV Randomized Study"],"prefix":"10.1002","volume":"72","author":[{"given":"Leonard H.","family":"Calabrese","sequence":"first","affiliation":[{"name":"Cleveland Clinic Foundation  Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Abud\u2010Mendoza","sequence":"additional","affiliation":[{"name":"Hospital Central  San Luis Potos\u00ed Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Lindsey","sequence":"additional","affiliation":[{"name":"Louisiana State University School of Medicine  Baton Rouge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang\u2010Heon","family":"Lee","sequence":"additional","affiliation":[{"name":"Konkuk University School of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Tatulych","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iikuni","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshika","family":"Soma","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center and University of Texas Southwestern Medical Center  Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz R","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39670"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22470"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"issue":"10","key":"e_1_2_8_6_1","first-page":"3027","article-title":"Herpes zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib [abstract]","volume":"68","author":"Winthrop KL","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40189"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420"},{"issue":"10","key":"e_1_2_8_13_1","first-page":"1520","article-title":"Safety, clinical and immunologic effectiveness of the live zoster vaccine administered to patients receiving anti\u2010TNF biologics [abstract]","volume":"67","author":"Curtis JR","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_14_1","unstructured":"US Food and Drug Administration.SHINGRIX (zoster vaccine recombinant adjuvanted) suspension for intramuscular injection highlights of prescribing information.2017. URL:https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581605.pdf."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.24010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:21:41Z","timestamp":1759425701000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1002\/acr.24010"],"URL":"https:\/\/doi.org\/10.1002\/acr.24010","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2019-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}